Stay updated on Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update or modification in the ongoing study related to the effectiveness of pembrolizumab in combination with BCG as a first-line therapy for high-risk T1 bladder cancer and high-grade upper tract urothelial carcinoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:45:45.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria,' which includes examples such as a person's general health condition or prior treatments. Additionally, detailed eligibility criteria for the study have been provided, including requirements for written informed consent and histologically confirmed urothelial cancer.
    Difference
    40%
    Check dated 2024-05-22T21:30:32.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:33:02.000Z thumbnail image

Stay in the know with updates to Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial page.